Shen Hai Long Capsule for Male Asthenospermia

• Status: Not yet recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

To evaluate the efficacy and safety of Shen Hai Long Capsule in the treatment of mild to moderate asthenospermia in men.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhongnan Hospital

Criteria

Inclusion Criteria:

1. Age range from 22 to 50 years old;

2. Patients with mild to moderate asthenospermia, that is, at least two normative semen analyses indicated that 10%≤PR percentage < 32% and the total number of PR sperm ranged from 5 million to 20 million;

3. At least two standard semen analyses indicated that sperm concentration ≥15×106 /ml; Sperm normal morphology rate ≥4%;

4. No other Chinese and Western drugs for the treatment of oligospermia, weak and malformed spermia have been taken in the past 3 months;

5. The subject voluntarily participates and signs the informed consent.

Exclusion Criteria:

1. Varicocele, ejaculatory duct/seminal vesicle cyst, anti-sperm antibody (+);

2. Genital tract infection: seminal plasmic elastase > 1000ng/ml or leukocyte semen disease (peroxidase positive cell concentration in semen more than 1×10^6/mL);

3. Erectile dysfunction, ejaculation disorders;

4. suffer from mental disorders, immune system diseases; Severe impairment of liver and kidney function (serum transaminase ≥2× upper limit of medical reference value, creatinine clearance ≤40ml/min or active stage of chronic kidney disease);

5. Patients with allergic history or constitution to therapeutic drugs;

6. Patients who have taken drugs affecting the study within 3 months, such as antitumor and antiepileptic drugs, etc.